Theodore K Marras1, Christopher Vinnard2, Quanwu Zhang3, Keith Hamilton4, Jennifer Adjemian5, Gina Eagle3, Raymond Zhang6, Engels Chou3, Kenneth N Olivier7. 1. Department of Medicine, University Health Network and Mount Sinai Hospital, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada. Electronic address: ted.marras@uhn.ca. 2. Public Health Research Institute, Rutgers, The State University of New Jersey, Newark, NJ, USA. 3. Insmed Inc., Bridgewater, NJ, USA. 4. University of Pennsylvania, Philadelphia, PA, USA. 5. Laboratory of Clinical Immunology and Microbiology, NIAID, USA; Commissioned Corps, United States Public Health Service, Rockville, MD, USA. 6. Orbis Data Solutions, Woburn, MA, USA. 7. Pulmonary Branch/NHLBI, National Institutes of Health, Bethesda, MD, USA.
Abstract
RATIONALE: The risk of all-cause mortality of nontuberculous mycobacterial lung disease (NTMLD) in the United States (US) population is not well established. OBJECTIVES: This study aims to assess the public health burden of NTMLD in the US by comparing the relative risk of all-cause mortality in the NTMLD population with an age- and sex-matched cohort from the general population. METHODS: Patients with physician claims for NTMLD (ICD-9 0.031; ICD-10 A31.0) were identified between 2007 and 2016 from a large US national managed care insurance plan covering approximately 15-18 million members annually. A control group with no NTMLD ICD-9 or 10 codes was randomly selected from the general population and matched 3:1 to the NTMLD sample according to birth year, gender, and insurance benefit coverage. The date of first NTMLD diagnosis of each patient was assigned to the matched controls as the index date. The Cox proportional hazard method compared survival between cohorts, adjusting for demographic factors and baseline comorbidities. RESULTS: A total of 2005 patients with NTMLD and 6014 controls were identified, with a mean follow-up duration of 3.4 years and 3.7 years, respectively. The NTMLD group had substantially higher proportions of patients with asthma (23.3% versus 3.5%), bronchiectasis (36.5% versus 0.1%), COPD (52.0% versus 5.9%), arrhythmia (22.6% versus 6.5%), coronary artery disease (18.5% versus 6.6%), heart failure (11.9% versus 4.1%), and cancer (18.5% versus 5.0%). The unadjusted rate of all-cause mortality from the index date was 20.7 per 1000 person-years in the NTMLD group vs 5.6 per 1000 person-years in the control group (rate ratio = 3.73; 95% CI: 2.93-4.75). Multivariable Cox regression, adjusted for the above variables as well as all other important baseline covariates, showed a doubling risk of all-cause mortality (hazard ratio [HR] = 2.06; CI: 1.52-2.79; P < 0.001) in the NTMLD vs control group. CONCLUSIONS: All-cause mortality, adjusted for other factors, more than doubled with NTMLD compared with an age-sex-matched control group in a large US national managed care insurance plan.
RATIONALE: The risk of all-cause mortality of nontuberculous mycobacterial lung disease (NTMLD) in the United States (US) population is not well established. OBJECTIVES: This study aims to assess the public health burden of NTMLD in the US by comparing the relative risk of all-cause mortality in the NTMLD population with an age- and sex-matched cohort from the general population. METHODS:Patients with physician claims for NTMLD (ICD-9 0.031; ICD-10 A31.0) were identified between 2007 and 2016 from a large US national managed care insurance plan covering approximately 15-18 million members annually. A control group with no NTMLD ICD-9 or 10 codes was randomly selected from the general population and matched 3:1 to the NTMLD sample according to birth year, gender, and insurance benefit coverage. The date of first NTMLD diagnosis of each patient was assigned to the matched controls as the index date. The Cox proportional hazard method compared survival between cohorts, adjusting for demographic factors and baseline comorbidities. RESULTS: A total of 2005 patients with NTMLD and 6014 controls were identified, with a mean follow-up duration of 3.4 years and 3.7 years, respectively. The NTMLD group had substantially higher proportions of patients with asthma (23.3% versus 3.5%), bronchiectasis (36.5% versus 0.1%), COPD (52.0% versus 5.9%), arrhythmia (22.6% versus 6.5%), coronary artery disease (18.5% versus 6.6%), heart failure (11.9% versus 4.1%), and cancer (18.5% versus 5.0%). The unadjusted rate of all-cause mortality from the index date was 20.7 per 1000 person-years in the NTMLD group vs 5.6 per 1000 person-years in the control group (rate ratio = 3.73; 95% CI: 2.93-4.75). Multivariable Cox regression, adjusted for the above variables as well as all other important baseline covariates, showed a doubling risk of all-cause mortality (hazard ratio [HR] = 2.06; CI: 1.52-2.79; P < 0.001) in the NTMLD vs control group. CONCLUSIONS: All-cause mortality, adjusted for other factors, more than doubled with NTMLD compared with an age-sex-matched control group in a large US national managed care insurance plan.
Authors: Kevin L Winthrop; Roger Baxter; Liyan Liu; Bentson McFarland; Donald Austin; Cara Varley; LeAnn Radcliffe; Eric Suhler; Dongsoek Choi; Lisa J Herrinton Journal: Pharmacoepidemiol Drug Saf Date: 2010-12-10 Impact factor: 2.890
Authors: Christopher Vinnard; Sarah Longworth; Alyssa Mezochow; Amee Patrawalla; Barry N Kreiswirth; Keith Hamilton Journal: Ann Am Thorac Soc Date: 2016-11
Authors: Meghan L O'Connell; Kate E Birkenkamp; David E Kleiner; Les R Folio; Steven M Holland; Kenneth N Olivier Journal: Chest Date: 2011-12-22 Impact factor: 9.410
Authors: Claire Andréjak; Vibeke Ø Thomsen; Isik S Johansen; Anders Riis; Thomas L Benfield; Pierre Duhaut; Henrik T Sørensen; François-Xavier Lescure; Reimar W Thomsen Journal: Am J Respir Crit Care Med Date: 2009-12-10 Impact factor: 21.405
Authors: Rebekah A Blakney; Emily E Ricotta; Dean Follmann; Jessica Drew; Kelly A Carey; Lisa N Glass; Chevalia Robinson; Sandra MacDonald; Pamela J McShane; Kenneth N Olivier; Kevin Fennelly; D Rebecca Prevots Journal: BMC Infect Dis Date: 2022-01-21 Impact factor: 3.090